CONTINUOUS INFUSION OF HIGH-DOSE CISPLATIN IN CHILDREN - PHARMACOKINETICS OF FREE AND TOTAL PLATINUM

被引:19
作者
BUESCHARBIT, M
GENTET, JC
BERNARD, JL
BREANT, V
CANO, JP
RAYBAUD, C
机构
[1] HOP ENFANTS TIMONE,SERV ONCOL PEDIAT,27 BLVD JEAN MOULIN,F-13385 MARSEILLE 5,FRANCE
[2] UNIV MARSEILLE HOSP,FAC PHARM,PHARMACOCINET LAB,U278,F-13385 MARSEILLE 5,FRANCE
来源
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1987年 / 23卷 / 11期
关键词
D O I
10.1016/0277-5379(87)90444-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A pharmacokinetic study was carried out in two infants and two (older) children with high-dose cisplatin (CP) (40 mg/m2/day) by 5-day continuous infusion. Following interruption of the infusion, the decrease in total plasma platinum was biphasic, with a terminal half-life of 155.5-418 h. During administration the urinary concentrations were between 7.66 and 15.2 mg/l. Thirty to thirty five per cent of the administered dose was eliminated within 48 h of discontinuing infusion. Free platinum (FP) levels declined in a biphasic manner, with a mean (± S.E.) elimination half-life of 81.25 (± 34.9) h. FP was still detectable in the plasma 10 days after the end of infusion with levels above 0.010 μg/ml. FP availability, measured as the area under the curves (AUC) of the FP concentration-up to 2 h after ending the infusion-were 768 (± 326) μg.min/ml. Inter- or intra-individual differences in AUC values were not observed. © 1987.
引用
收藏
页码:1649 / 1652
页数:4
相关论文
共 17 条
[1]  
BUESCHARBIT M, 1982, CANCER CHEMOTHER P S, V9, P8
[2]   Platinum Determination in Plasma and Urine by Flameless Atomic Absorption Spectrophotometry [J].
Cano, J. P. ;
Catalin, J. ;
Bues-Charbit, M. .
JOURNAL OF APPLIED TOXICOLOGY, 1982, 2 (01) :33-38
[3]   CLINICAL-PHARMACOLOGY OF HIGH-DOSE CISPLATIN [J].
CORDEN, BJ ;
FINE, RL ;
OZOLS, RF ;
COLLINS, JM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1985, 14 (01) :38-41
[4]   CISPLATIN METABOLITES IN PLASMA, A STUDY OF THEIR PHARMACOKINETICS AND IMPORTANCE IN THE NEPHROTOXIC AND ANTITUMOUR ACTIVITY OF CISPLATIN [J].
DALEYYATES, PT ;
MCBRIEN, DCH .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (19) :3063-3070
[5]   THE INHIBITION OF RENAL ATPASE BY CISPLATIN AND SOME BIOTRANSFORMATION PRODUCTS [J].
DALEYYATES, PT ;
MCBRIEN, DCH .
CHEMICO-BIOLOGICAL INTERACTIONS, 1982, 40 (03) :325-334
[6]  
DEGREGORIO MW, 1985, CANCER CHEMOTH PHARM, V15, P183
[7]  
DREWINKO B, 1973, CANCER RES, V33, P3091
[8]  
EARHART RH, 1983, CANCER RES, V43, P1187
[9]   EFFECT OF MANNITOL AND PLASMA ON THE CYTO-TOXICITY OF CISPLATIN [J].
HOLDENER, EE ;
PARK, CH ;
BELT, RJ ;
STEPHENS, RL ;
HOOGSTRATEN, B .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (04) :515-518
[10]  
LOKICH JJ, 1980, CANCER TREAT REP, V64, P905